RLYB News and Press, Rallybio Corporation From 01/31/23

Rallybio ( NASDAQ: RLYB ) on Tuesday said it had appointed Jonathan Lieber as its CFO, effective Feb 1. Lieber succeeds RLYB co-founder Jeffrey Fryer, the company said in a statement . Fryer's departure was announced by the company in June last year. According to RLYB...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company’s Chief Financia...

-- Phase 1b Proof-of-Concept Data for RLYB212 on track for 1Q 2023 -- -- Initiated Phase 1 Multiple Ascending Dose Study of RLYB116 in 4Q 2022; Safety, PK and PD Data Expected in 2H 2023 -- -- Cash Runway Extended into 1Q 2025 following November 2022 Follow-On Offering -- ...

Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...

-- Data Demonstrates that HPA-1a Alloimmunization can be Prevented with Prophylactic Administration of Low Levels of HPA-1a-specific Antibodies -- Rallybio Corporation (Nasdaq: RLYB) today announced publication of preclinical study results for two human HPA-1a-specific antibodies in...

JP Morgan has initiated Rallybio ( NASDAQ: RLYB ) with an overweight rating due to a positive outlook on the company's lead asset RLYB212, for the prevention of fetal and neonatal alloimmune thrombocytopenia. The firm has a $21 price target (339% upside based on Thursday's close). ...

AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera&#...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferenc...

Rallybio Corporation ( NASDAQ: RLYB ) has priced an underwritten public offering of 5M shares of its common stock at a price to the public of $6.00/share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares o...